Please login to the form below

Not currently logged in
Email:
Password:

Ibrance

This page shows the latest Ibrance news and features for those working in and with pharma, biotech and healthcare.

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

Outside the US, CDK4/6 inhibitor Ibrance was also up by 21%, while sales of tyrosine kinase inhibitor (TKI) Inlyta also increased by 29% globally following increased adoption in the US ... In addition, sales of Ibrance in the US dropped by 7% as the

Latest news

More from news
Approximately 23 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others.

  • Integrating electronic health records into clinical trials Integrating electronic health records into clinical trials

    Pfizer, for example, won an expanded FDA label for breast cancer drug Ibrance on the strength of data from sources including EHRs.

  • The evolution of real-world studies The evolution of real-world studies

    Analyses of real-world tumour responses and safety data persuaded the FDA that Ibrance is safe and effective in men, leading it to expand the label. ... Ibrance gained a new approval based on data from EHRs and other real-world sources.

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    This includes overriding pharma patents – something the group is advocating in relation to three drugs – Vertex’s cystic fibrosis treatment Orkambi, Pfizer’s breast cancer treatment Ibrance and Roche’s breast

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... Breast cancer drug Ibrance will be one of the biggest growth drivers for the company, as it looks

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...